Using different primary melanoma cells bearing BRAFV600 mutations, we recently established that cell exposure to Vemurafenib/PLX4032 upregulates HO-1 expression that, in turn, reduces drug efficacy, by limiting drug-induced cell death and NK cell dependent recognition and killing [17]. The gene discussed is HMOX1; the disease is melanoma.